New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
08:30 EDTREGNRegeneron and Avalanche Biotechnologies sign development collaboration
Regeneron and Avalanche Biotechnologies announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron. Avalanche will receive an upfront cash payment, contingent payments of up to $640M upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. The collaboration covers up to eight distinct therapeutic targets, and Regeneron will have exclusive worldwide rights for each product it moves forward in clinical development.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:51 EDTREGNBofA/Merrill biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:31 EDTREGNRegeneron price target raised to $462 from $418 at BofA/Merrill
Subscribe for More Information
November 20, 2014
07:47 EDTREGNRegeneron price target raised to $450 from $390 at Brean Capital
Subscribe for More Information
05:22 EDTREGNRegeneron, Sanofi receive FDA Breakthrough Therapy designation in AD
Subscribe for More Information
November 19, 2014
08:17 EDTREGNRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
November 18, 2014
05:43 EDTREGNRegeneron announces EYLEA injection approved for DME treatment in Japan
Subscribe for More Information
November 12, 2014
08:13 EDTREGNBoston Biotech to hold a conference
Subscribe for More Information
November 11, 2014
10:14 EDTREGNRegeneron data reinforce blockbuster potential of dupilumab, says Piper Jaffray
Piper Jaffray believes the Phase IIb results for dupilumab in patients with moderate to severe asthma reported by Regeneron (REGN) and partner Sanofi (SNY) reinforce the broad potential of the drug in a range of allergic diseases. The firm reiterates its $416 price target and Overweight rating on shares of Regeneron.
05:26 EDTREGNRegeneron, Sanofi announce dupilumab Phase 2b study met primary endpoint
Subscribe for More Information
November 10, 2014
07:19 EDTREGNCredit Suisse to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use